Management of Mobitz Type 1 with IV Bolus Administration

Introduction to Mobitz Type 1 Management

The American College of Cardiology recommends avoiding AV nodal blocking agents in patients with Mobitz Type 1, as they can worsen conduction through the AV node 1
The American College of Cardiology suggests that most other IV medications can be administered safely to patients with Mobitz Type 1, as long as they don't have AV nodal blocking properties 1

Beta-blockers, such as esmolol, metoprolol, and propranolol, are contraindicated in patients with AV block greater than first degree or SA node dysfunction, unless a pacemaker is present 1
Non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, carry the same contraindication for AV block greater than first degree 1
Adenosine should be used with caution in patients with Mobitz Type 1, as it can cause transient AV block and is contraindicated in AV block greater than first degree without a pacemaker 1
Digoxin slows AV nodal conduction and should be avoided in patients with Mobitz Type 1 1

The American College of Cardiology recommends assessing hemodynamic status before administering an IV bolus to a patient with Mobitz Type 1, and considering atropine 0.5 mg IV bolus if the patient is symptomatic with hypotension or bradycardia 2
Atropine may be therapeutic for symptomatic Mobitz Type 1 at the AV node level, but doses less than 0.5 mg may paradoxically slow heart rate due to parasympathomimetic effects 2

Mobitz Type 1 typically occurs at the AV node level, but rare cases of infranodal Mobitz Type 1 exist and carry a worse prognosis similar to Mobitz Type 2 2, 3
A wide QRS complex may suggest infranodal disease, which carries a higher risk of progression to complete heart block 5

The American College of Cardiology warns against assuming all Mobitz Type 1 is benign, as infranodal Mobitz Type 1 exists and carries significant risk of progression to complete heart block 2, 3

Continuous cardiac monitoring is essential when administering any IV bolus to a patient with Mobitz Type 1, to monitor for progression to higher-grade block and assess for hemodynamic compromise 4